Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

We hypothesised that the prognostic nutrition index (PNI) is useful for evaluating host immunity and response to immune checkpoint inhibitors. We investigated the effect of PNI on nivolumab monotherapy efficacy in advanced or recurrent gastric cancer (GC) or gastro-oesophageal junction cancer (GOC) patients. We retrospectively examined 110 patients, divided them into a high-PNI group and a low-PNI group, and compared treatment efficacy, adverse events (AEs), and survival between the groups. Median overall survival (OS) was significantly longer in the high-PNI group than in the low-PNI group (205 vs. 109 days; p<0.001). Multivariate analysis revealed that low PNI was an independent risk factor for OS (hazard ratio=2.398; 95% confidence interval=1.384-4.154; p=0.002). The overall response rate and frequency of AEs were not significantly different between the groups. PNI could be a useful prognostic factor in GC or GOC patients undergoing nivolumab monotherapy. Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.


Hayato Watanabe, Takanobu Yamada, Keisuke Komori, Kentaro Hara, Kazuki Kano, Kosuke Takahashi, Yuta Kumazu, Hirohito Fujikawa, Masakatsu Numata, Toru Aoyama, Hiroshi Tamagawa, Yasuhiro Inokuchi, Nozomu Machida, Manabu Shiozawa, Norio Yukawa, Soichiro Morinaga, Yasushi Rino, Munetaka Masuda, Takashi Ogata, Takashi Oshima. Effect of Prognostic Nutrition Index in Gastric or Gastro-oesophageal Junction Cancer Patients Undergoing Nivolumab Monotherapy. In vivo (Athens, Greece). 2021 Jan-Feb;35(1):563-569

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 33402510

View Full Text